News updated today Live desk
For publishersAbout
Breaking
Follow latest
Back to latest stories
World

Biocon’s Pebrilzo becomes first biosimilar approved under EMA’s tailored clinical pathway

The approval marks a regulatory milestone for Biocon and expands its portfolio of oncology biosimilars approved in Europe and the United States.

BU
Originally published byBusiness Line - Home 27m ago · thehindubusinessline.com
Read full report at Business Line - Home

NewsBeagle is a discovery engine. We show the headline, a short source-supplied summary and clear attribution. The complete reporting remains with the publisher.